IL3RA and acute myeloid leukemia: Since the combination of AZA with anti-CD123 CAR T cells did not cause epithelial tissue damage or significant hematopoietic insufficiency, our findings pave the way for a clinical trial combining AZA and anti-CD123 CAR T cells for AML treatment.